Regeneron Pharmaceuticals Inc (NASDAQ:REGN)‘s stock had its “buy” rating reaffirmed by equities research analysts at Credit Suisse Group AG in a research report issued on Friday. They currently have a $485.00 target price on the biopharmaceutical company’s stock. Credit Suisse Group AG’s price objective points to a potential upside of 13.05% from the company’s current […]
